NIKKEI 225
28,455.60 +528.23 (+1.89%) HANG SENG
23,983.66 +634.28 (+2.72%) CRUDE OIL
72.06 +2.57 (+3.70%) GOLD FUTURES
1,786.10 +6.60 (+0.37%) DOW
35,730.66 +503.63 (+1.43%) BTC-GBP
38,612.05 +1,224.05 (+3.27%)
Merus N.V. (MRUS)
| Previous close | 25.91 |
| Open | 25.83 |
| Bid | 26.28 x 800 |
| Ask | 26.40 x 800 |
| Day's range | 24.42 - 25.93 |
| 52-week range | 15.68 - 33.00 |
| Volume | |
| Avg. volume | 523,839 |
| Market cap | 1.016B |
| Beta (5Y monthly) | 0.64 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Globe Newswire
Merus Presents Clinical Data on MCLA-145 at the ESMO Immuno-Oncology Congress 2021
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today released clinical data on MCLA-145 from the phase 1 trial in patients with solid tumors at the ESMO Immuno-Oncology Congress 2021 being held virtually. “We are encouraged by the progress we are making with MCLA-145,” said
- Globe Newswire
Merus Announces Poster Presentation on Clinical Data on MCLA-145 at the ESMO Immuno-Oncology Congress 2021
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the publication of the abstract highlighting interim data, as of a July 14, 2021 cutoff, from the phase 1/2 trial of bispecific antibody MCLA-145 in patients with solid tumors. The e-poster will be presented at
- Globe Newswire
Merus to Participate in a Fireside Chat at the Jefferies London Healthcare Conference (Virtual)
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Bill Lundberg, M.D., Chief Executive Officer of Merus, will participate in a fireside chat at the Jefferies London Healthcare Conference (Virtual). The prerecorded fireside chat will be available starting on Thursday, November 18, 2021 at 8:00 am
